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Background: Recently, the International Agency for Research on Cancer (IARC) Programme for the
Evaluation of Carcinogenic Risks to Humans has been criticized for several of its evaluations, and also for
the approach used to perform these evaluations. Some critics have claimed that failures of IARC Working
Groups to recognize study weaknesses and biases of Working Group members have led to inappropriate
classification of a number of agents as carcinogenic to humans.
Objectives: The authors of this Commentary are scientists from various disciplines relevant to the identification and hazard evaluation of human carcinogens. We examined criticisms of the IARC classification
process to determine the validity of these concerns. Here, we present the results of that examination,
review the history of IARC evaluations, and describe how the IARC evaluations are performed.
Discussion: We concluded that these recent criticisms are unconvincing. The procedures employed by
IARC to assemble Working Groups of scientists from the various disciplines and the techniques followed
to review the literature and perform hazard assessment of various agents provide a balanced evaluation
and an appropriate indication of the weight of the evidence. Some disagreement by individual scientists
to some evaluations is not evidence of process failure. The review process has been modified over time and
will undoubtedly be altered in the future to improve the process. Any process can in theory be improved,
and we would support continued review and improvement of the IARC processes. This does not mean,
however, that the current procedures are flawed.
Conclusions: The IARC Monographs have made, and continue to make, major contributions to the
scientific underpinning for societal actions to improve the public’s health.
Citation: Pearce N, Blair A, Vineis P, Ahrens W, Andersen A, Anto JM, Armstrong BK, Baccarelli AA,
Beland FA, Berrington A, Bertazzi PA, Birnbaum LS, Brownson RC, Bucher JR, Cantor KP, Cardis E,
Cherrie JW, Christiani DC, Cocco P, Coggon D, Comba P, Demers PA, Dement JM, Douwes J,
Eisen EA, Engel LS, Fenske RA, Fleming LE, Fletcher T, Fontham E, Forastiere F, Frentzel-Beyme R,
Fritschi L, Gerin M, Goldberg M, Grandjean P, Grimsrud TK, Gustavsson P, Haines A, Hartge P,
Hansen J, Hauptmann M, Heederik D, Hemminki K, Hemon D, Hertz-Picciotto I, Hoppin JA, Huff J,
Jarvholm B, Kang D, Karagas MR, Kjaerheim K, Kjuus H, Kogevinas M, Kriebel D, Kristensen P,
Kromhout H, Laden F, Lebailly P, LeMasters G, Lubin JH, Lynch CF, Lynge E, ‘t Mannetje A,
McMichael AJ, McLaughlin JR, Marrett L, Martuzzi M, Merchant JA, Merler E, Merletti F, Miller A,
Mirer FE, Monson R, Nordby KC, Olshan AF, Parent ME, Perera FP, Perry MJ, Pesatori AC, Pirastu R,
Porta M, Pukkala E, Rice C, Richardson DB, Ritter L, Ritz B, Ronckers CM, Rushton L, Rusiecki JA,
Rusyn I, Samet JM, Sandler DP, de Sanjose S, Schernhammer E, Seniori Costantini A, Seixas N, Shy C,
Siemiatycki J, Silverman DT, Simonato L, Smith AH, Smith MT, Spinelli JJ, Spitz MR, Stallones L,
Stayner LT, Steenland K, Stenzel M, Stewart BW, Stewart PA, Symanski E, Terracini B, Tolbert PE,
Vainio H, Vena J, Vermeulen R, Victora CG, Ward EM, Weinberg CR, Weisenburger D, Wesseling C,
Weiderpass E, Zahm SH. 2015. IARC Monographs: 40 years of evaluating carcinogenic hazards to
humans. Environ Health Perspect 123:507–514; http://dx.doi.org/10.1289/ehp.1409149

Introduction
Important advances in human health have
come from the recognition of health hazards
and the development of policy actions to
address them (Brownson et al. 2009; Espina
et al. 2013; Samet 2000). Government and
nongovernmental organizations use expert
panels to review the scientific literature
and to assess its relevance to public health
policies. Scientific experts are charged with
reviewing the quality and quantity of the
scientific evidence and providing scientific

interpretations of the evidence that underpin
a range of health policy decisions.
The IARC Monographs on the Evaluation
of Carcinogenic Risks to Humans of the
International Agency for Research on Cancer
(IARC) are a prominent example of such
an expert review process. The goal of the
Monograph Programme is to assess carcinogenic hazards from occupational, environmental, and lifestyle exposures and agents,
thus providing an essential step in the societal
decision-making process to identify and

then control carcinogenic hazards. For these
evaluations, IARC assembles groups of scientists with a range of relevant scientific expertise (called “Working Groups”) to review and
assess the quality and strength of evidence
from informative publications and perform a
hazard evaluation to assess the likelihood that
the agents of concern pose a cancer hazard
to humans (Tomatis 1976). IARC has used
this approach for four decades, since the first
Monograph in 1972 (IARC 1972). Although
widely accepted intern ationally, there
have been criticisms of the classification of
particular agents in the past, and more recent
criticisms have been directed at the general
approach adopted by IARC for such evalua
tions (Boffetta et al. 2009; Epidemiology
Monitor 2012; Ioannidis 2005; Kabat 2012;
McLaughlin et al. 2010, 2011).
The Monographs are widely used and
referenced by governments, organizations,
and the public around the world; therefore,
it is critical that Working Group conclusions
be clear and transparent. In addition to the
actual evaluation, a major contribution of
the Monographs is the assembly of relevant
literature and its dissemination to the public.
We recognize that no system of evaluation is
perfect. It is important to foster continuing
improvement of the methods used by IARC
and other bodies that review scientific
evidence. The IARC process itself has been
modified from time to time (e.g., addition of
specific evaluation of mechanistic data and
greater use of formal meta-analyses and datapooling approaches). Indeed, as recently as
April 2014, the IARC Monographs program
has been a subject of a review by the Advisory
Group to recommend priorities for IARC
Monographs during 2015–2019 (Straif
et al. 2014). The Advisory Group has made
a number of recommendations on further
improvements in the Monographs process
specifically related to conflict of interest,
transparency, and the use of the systematic
review procedures in data gathering and
evaluation. Thus, possible changes to the
process are periodically considered by IARC
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governing groups (Scientific Council and
Governing Council) and Advisory Groups.
Here, we focus on current IARC processes
and practices because these have been the
focus of recent criticisms. The authors of this
Commentary are scientists from a wide range
of disciplines who are involved in designing
and conducting studies that provide data
used in hazard evaluations, such as those
performed by IARC. Many (but not all) of us
have served on IARC Monograph Working
Groups, but none are current IARC staff. We
first discuss the history of IARC, and describe
how the IARC evaluations are performed in
order to foster evidence-based policy. We
then describe why unbiased evaluations,
based on the evidence and free of conflicts
of interest, are necessary for public health
decision making. Finally, we discuss the
recent criticisms of the IARC approach.

The IARC Monographs
History of the IARC Monographs. Shortly
after IARC’s establishment, its parent entity,
the World Health Organization (WHO),
asked IARC to prepare a list of agents known
to cause cancer in humans. IARC recognized
the need for a systematic process to determine
which agents should be listed. Such a process
was launched in 1972 by Lorenzo Tomatis,
then Chief of the Division of Carcinogenicity
of IARC (Tomatis 1976). IARC is funded by
the governments of 24 countries that have
decided to become members, in addition to
competitive grants from funding agencies.
The IARC Monograph Programme is
mainly funded by the U.S. National Cancer
Institute through a renewable grant subject
to peer review of the program. Other sources
of external funding have included the
European Commission Directorate-General
of Employment, Social Affairs and Equal
Opportunities; the U.S. National Institute of
Environmental Health Sciences; and the U.S.
Environmental Protection Agency.
The IARC process antedates current
systematic review methods, but anticipated
some of them, for example, with regard to
transparent literature identification. In the
IARC process, agents are assessed for carcinogenic hazard and assigned to one of five categories, ranging from carcinogenic to humans
to probably not carcinogenic to humans
(Appendix 1). The classification categories are
described in the preamble to the Monographs
(IARC 2006). Carcinogenic hazard identification refers to an assessment of whether an agent
causes cancer. Hazard identification does not
predict the magnitude of cancer risks under
specific conditions; this can be determined only
with appropriate exposure–response information (National Research Council 2009).
The IARC Monograph process. The process
for the preparation of an IARC Monograph
Environmental Health Perspectives •

volume

is clearly described in the Preamble, which is
published as part of each Monograph (e.g.,
IARC 2014a). It starts with the nomination
of candidate agents. Nominations come from
national regulatory agencies, scientists, and
stakeholders, including public health professionals, experts in environmental or occupational hygiene, industry representatives,
and private citizens. It is important to note
that anyone (including private citizens) can
participate in the nomination process. The
Monograph Programme convenes meetings
of special Advisory Groups (composed of
external scientists that possess a broad range
of relevant professional skills) to review agents
nominated for evaluation and to suggest
IARC priorities for such reviews (Ward et al.
2010). Announcements of a review are made
on the IARC website (http://monographs.iarc.
fr/ENG/Meetings/). For example, in 2013
IARC sought nominations for agents to be
evaluated in 2015–2019 (IARC 2014b). An
Advisory Group reviewed the nominated
agents and exposures, added several new ones,
and discussed the priorities for each.
The IARC staff makes the final selection
of agents for review by taking into account
the prevalence and intensity of exposure (of
both occupational groups and the general
population) and availability of sufficient
literature for an evaluation of carcinogenicity,
as well as advice from the Advisory Groups.
The large majority of evaluations concern
specific compounds, but there are also monographs on various occupations or industries,
for example, aluminum production, insecticide applicators, firefighters, manufacture of
leather goods, leather tanning and processing,
welding, painters, petroleum refining, and
pulp and paper manufacturing. Some individual exposures that occur in these settings
have also been evaluated.
The next step is the selection of members
of the Working Group (WG). IARC staff
review the literature to identify Working
Group candidates and specialists in relevant
areas of expertise; they also seek names
of possible candidates from the scientific
community and advisory groups. The list of
potential members, including disclosure of
relevant conflicts of interest, is posted on the
IARC website (http://monographs.iarc.fr/
ENG/Meetings/) before the WG is convened,
and anyone can send comments. Members
are typically scientists who have conducted
research relevant to the agent under review,
but not necessarily on the specific agent.
Selection procedures are evaluated yearly by
the Scientific and the Governing Councils.
The IARC Section of Monographs also
has an external Advisory Board, made up
of independent scientists, that periodically
peer reviews its activities. In addition to
Working Group members, invited specialists,
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representatives of health agencies, stakeholder
observers, and the IARC Secretariat also
attend meetings.
The responsibility of the Working
Group is to review the literature before the
Monograph meeting, discuss the literature
at the meeting, and then classify whether an
agent is carcinogenic, probably carcinogenic,
possibly carcinogenic, not classifiable, or
probably not carcinogenic to humans (see
Appendix 1). Working Group members
are also responsible for writing the IARC
Monograph, which must both review the
literature and explain why the Working
Group came to their specific conclusions.
The procedures used to evaluate the scientific evidence are described in the Preamble
to the Monographs (IARC 2006). It is
important to stress that only Working Group
members conduct the actual evaluation (Wild
and Cogliano 2011; Wild and Straif 2011).
IARC staff facilitate the evaluation process and
ensure that the procedures described in the
Preamble are followed; however, they do not
determine the outcomes.
IARC assessments of carcinogenicity
are based on, and necessarily limited to,
scientific evidence available at the time
of the review. The evidence comes from
epidemiologic studies, animal bioassays,
pharmacokinetic/mechanistic experiments,
and surveys of human exposure. The aim is
to include all relevant papers on cancer in
humans and experimental animals that have
been published, or accepted for publication,
in peer-reviewed scientific journals and also
any publicly available government or agency
documents that provide data on the circumstances and extent of human exposure. To
that end, the search of the literature takes a
comprehensive approach. Papers that are
found not to provide useful evidence can be
excluded later in the process. IARC staff first
use previous IARC Monographs (if available),
database searches using relevant text strings,
and contact with investigators in the field to
identify potentially relevant material. Thus, the
initial assembly of the literature is performed
by individuals who are not engaged in the
actual evaluation. Working Group members
are then assigned various writing tasks and
are instructed to perform their own literature
searches to identify any further papers that
might have been missed. In addition, all of the
papers assembled by IARC are made available
to the full Working Group before they meet,
and any member can recommend other papers
not previously identified that they think should
be considered. Finally, papers can be recommended by stakeholder representatives before
or during the Working Group meeting.
At the meeting of the Working Group,
the assembled documents are reviewed and
summarized by discipline-related subgroups.
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However, any member of the Working Group
has access to all of the assembled literature. The
summaries are distributed to all subgroups, and
information from all disciplines is discussed in
plenary sessions prior to assigning the agents to
a specific carcinogenicity category.
Because new findings continually emerge
in the literature, agents are reconsidered when
IARC and IARC Advisory Groups judge
that there is sufficient additional information
that might alter a previous evaluation. Thus,
conclusions regarding human carcinogenicity
of particular substances may change as new
evidence becomes available. For some agents,
this reevaluation has resulted in progression toward greater certainty regarding their
human carcinogenicity, whereas for others
the progress has been moved toward less
certainty. Such movements are expected in
an open, transparent, and evidence-based
process. A comprehensive update of all
Group 1 carcinogens was recently accomplished in Volume 100 A through F (http://
monographs.iarc.fr/ENG/Monographs/
PDFs/index.php).
Usually, several agents are evaluated in a
single meeting lasting more than 1 week. After
discussing the evidence fully, the Working
Group members follow the published IARC
procedures for combining information from
epidemiologic studies and bioassays to arrive
at a preliminary classification (IARC 2014a).
Mechanistic data are then considered in order
to determine whether they warrant a change
from the preliminary classification. The
Working Group then votes on the final determination. Many votes are unanimous, but on
occasion some reviewers may favor a higher
or lower ranking than the majority. When
there is dissent, alternative interpretations
and their underlying reasoning are sometimes
reported in the rationale for the evaluation if
the dissenters feel their point of view is not
sufficiently addressed in the monograph.
Consideration of the totality of the
evidence. IARC Working Groups make
every effort to provide full and transparent
documentation of what evidence was
assembled, how it was evaluated, and which
papers were most important for the hazard
evaluation. Consequently, the monographs
are often quite lengthy, containing many
evidence tables [see, for example, the recent
monograph on trichloroethylene (IARC
2014c)]. Evaluations involve consideration
of all of the known relevant evidence from
epidemiologic, animal, pharmacokinetic/
mechanistic, and exposure studies to assess
cancer hazard in humans. Information on
human exposure is not formally graded as
part of the overall assessment of carcinogenic
hazard; however, these data make a critical
contribution to the process by charac
terizing the timing, duration, and levels of
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exposure in the population, and in evaluating
the quality of the exposure assessment in
epidemiologic studies.
Doubts and criticisms have sometimes
been expressed about the relative weights
attributed to evidence from individual disciplines to the assessment of cancer hazards to
humans; however, each discipline provides
important evidence toward the overall evaluation of causality according to the Bradford
Hill considerations (Hill 1965). Because the
totality of the evidence is considered, deficiencies in one discipline are often offset by
strengths in another. For example, epidemiologic studies may focus on population-relevant
exposures, whereas findings from animal
experiments usually involve higher exposures
but are less susceptible to confounding.
Long-term animal bioassays and mechanistic studies provide critical information on
the capacity of an agent to produce cancer
in mammalian systems, including humans,
and to contribute to decisions that would
lead to better protection of human health.
Bioassays are the backbone of regulatory
science because they provide the opportunity to rigorously evaluate potential hazards
before there is widespread human exposure.
Bioassays and mechanistic studies are sometimes criticized for employing exposure routes
and doses that in most instances humans
would not experience, although experimental
dose categories sometimes approach exposure
levels found in occupational situations. There
is evidence that carcinogenicity in human and
animal studies is often concordant, although
data may differ as to the affected cancer site
(Haseman 2000; Maronpot et al. 2004;
Tomatis 2002). A major effort to evaluate
the concordance between animal and human
results is currently under way; two Working
Groups were convened at IARC in 2012, and
a systematic evaluation of the correspondence
between human and animal data was undertaken (a report is not yet publicly available).

Criticisms of the IARC Process
IARC Monographs are widely used to
identify potential carcinogenic hazards to
humans and serve as reference documents
summarizing the literature on many different
agents. In recent years, however, individuals
have criticized both the classification of individual agents as well as the general evaluative
approach (Boffetta et al. 2009; Epidemiology
Monitor 2012; Kabat 2012; McLaughlin
et al. 2010, 2011). We discuss four of these
criticisms below.
Criticisms of epidemiology. Some of the
criticisms of the IARC process have occurred
in the context of more general criticisms
of epidemiology as a science (Kabat 2008);
these were discussed in detail by Blair et al.
(2009). Potential methodological weaknesses
volume

for observational epidemiologic studies are
well recognized and can be found in any
epidemiologic textbook (Checkoway et al.
2004; Rothman et al. 2008). Most studies
are subject to one or more methodological
limitations, but this does not necessarily
invalidate their findings (Blair et al. 2009).
In fact, the value of epidemiologic studies has
been shown by the identification of a number
of well-established human carcinog ens,
including tobacco, asbestos, benzene, hexa
valent chromium, and some viruses, in
multiple studies. Some critics also argue that
small or nonexistent health risks are unjustifiably highlighted and hyped by researchers who
have a vested interest in continued research
funding and the need to publish to benefit
their careers (Boffetta et al. 2008; Kabat
2008; McLaughlin et al. 2010, 2011; Taubes
1995). However, such overstated results are
unlikely to exert much of an influence in a
Monograph because IARC evaluations are
based on the totality of the evidence. The
problem would have to occur in multiple
studies, and the Working Group would have
to be unable to identify it or be unwilling to
weigh such studies appropriately. Incorrect
positive conclusions regarding carcinogenicity
may also occur in reviews of multiple studies
because of publication bias, which may
selectively populate the literature only with
“positive” findings. However, once a topic is
recognized as scientifically important, reports
on relevant studies will be published regardless
of the findings, so publication bias is mainly a
concern for newly arising issues. To evaluate
the potential for publication bias, Working
Groups consider whether stronger negative
studies (both in terms of design and sample
size) have emerged after publication of an
initial cluster of smaller and/or weaker positive
studies. Funnel plots help in the assessment
of bias relating to sample size and publication bias (Borenstein et al. 2009). In contrast,
there are no established statistical techniques
to clearly characterize strength of design.
One of the distinctive features of epidemiology is that criticism and self-criticism
are firmly embedded in the discipline. A
great deal of work has been done on developing methods for critical appraisal (Elwood
2007) and for assessing the likely strength
and direction of possible biases (Rothman
et al. 2008). Epidemiologists and other
members on Working Groups routinely use
various approaches to assess possible bias in
study design and analysis when weighing the
strengths of different studies.
The issue of false positives. Epidemiology
specifically has been criticized for a tendency
to produce false-positive results (i.e., individual study associations not borne out by
the weight of the evidence) or to preferentially report positive findings over negative
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or inconclusive findings (i.e., publication
bias) (Boffetta et al. 2008, 2009; Ioannidis
2005; Kabat 2012; McLaughlin and Tarone
2013). This criticism has been most often
applied to potential false positives from
individual studies, but it has been inferred
that this problem may also apply to overall
hazard evaluations, which use findings from
multiple studies. We will consider each of
these issues in turn.
False-positive findings may occur by
chance, particularly when many combinations
of exposures and health outcomes have been
examined in a single study without strong
prior expectations of association; this happens
often, for example, in genome-wide association studies where thousands of gene–disease
associations are evaluated. Chance, of course,
operates in all disciplines and in both observational and experimental studies. However,
there are well-known statistical techniques
to reduce the probability of declaring chance
findings as “positive” (Rothman et al. 2008).
Independent replication, however, is the most
convincing way of checking for “chance”
findings; hazard evaluations, such as those
conducted by IARC Working Groups, rely
heavily on reproducibility in independent
studies and also interpret data following
Bradford Hill principles (Hill 1965).
False negatives are more difficult to
address, and perhaps they occur more
frequently than false positives because of low
statistical power, nond ifferential misclassification of exposure and/or outcome, and
incomplete follow-up, which tends to reduce
the observed difference in risk between
the exposed and none xposed populations
(Ahlbom et al. 1990; Blair et al. 2009;
Grandjean 2005; Rothman et al. 2008). A
new positive association stimulates research,
whereas studies finding no associations tend
to stifle further work.
There are difficulties in conducting
epidemiologic studies of agents that are relatively “weak” carcinogens, or for stronger
carcinogens where exposure is very low
because bias and confounding can obscure
weak positive associations (MacMahon et al.
1981). In general, weak carcinogens and low
levels of exposure result in a smaller “signalto-noise” ratio making the real signal more
difficult to detect. Although the identification of small relative risks to humans poses
special challenges to scientific research, the
refinement of study designs, improvements
in methods of exposure assessment, and the
use of biomarkers have helped to address the
problems (e.g., newer studies on the effects
of air pollution, the growth in opportunities to examine gene–environment interactions) (Gallo et al. 2011). In some situations,
there is less of a problem. For example, in
occupational studies, exposures and relative
Environmental Health Perspectives •
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risks may be higher while differences in
lifestyle factors between different groups of
workers are smaller (Checkoway et al. 2004);
thus, any confounding by nonoccupational
factors is likely to be weak, even from potent
causes of cancer such as cigarette smoking
(Siemiatycki et al. 1988). Of course, the
interpretation of such studies is enhanced
when there is supporting evidence from bioassays and/or mechanistic studies.
False-positive and false-negative findings
in individual studies may arise by chance
or bias, including bias due to confounding
(Rothman et al. 2008). However, the evalua
tion of multiple independent epidemiologic
studies from various geographic locations,
involving a variety of study designs, as well as
evidence from experimental studies, reduces
the possibility that false-positive findings from
any individual study influences the overall
evaluation process. Some studies may have
greater influence than others because of methodological strengths and/or large sample size.
The use of information from a variety of study
designs reduces the likelihood of false-positive
evaluations because it is unlikely that the same
biases will occur in multiple studies based on
different populations under different study
designs. Moreover, apparently conflicting
results from epidemiologic studies do not
necessarily indicate that some are false positive
or false negative. This might, for example,
reflect differences in levels of exposure or
susceptibility to the effects of exposure
(effect modification). Finally, judgment by
the Working Group is not based exclusively
on epidemiologic studies but usually also
on results from laboratory and mechanistic
studies that provide further evidence and
biological coherence. For the Monographs
that evaluate carcinogenic hazards associated
with specific occupations or industries, the
exposures of interest usually involve a complex
mixture of chemicals. For these evaluations,
most information comes from epidemiologic
studies, although exposures to individual
agents occurring at these workplaces may have
been evaluated in experimental studies.
Discontent with IARC Monograph
processes. The IARC Monograph evaluation
process has been criticized and it has been
alleged that “a number of scientists with
direct experience of IARC have felt compelled
to dissociate themselves from the agency’s
approach to evaluating carcinogenic hazards”
(Kabat 2012). This is a serious charge.
However, the author of this claim provided
no evidence to support the charge that a
“number of scientists” have dissociated themselves from the process, nor has there been
any indication of how many scientists have
taken this step, or for what reason. In science,
we expect sweeping statements such as this to
be appropriately documented. We have not
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been able to identify any credible support for
this contention.
There is an IARC Governing Council
and a Scientific Council to provide oversight
and guidance to the agency. The Governing
Council represents the participating states
and sets general IARC policy. It appoints the
IARC Director and members of the Scientific
Council. The latter are independent scientists
who are selected to provide scientific expertise and not as representatives of the member
states. They serve for 4 years and serve without
pay. The voting members of Monograph
Working Groups are not employed by IARC,
and they perform this task without financial
compensation. There have been 111 volumes,
including six separate documents under
Volume 100, and three Supplements. Over
the years, as the number of publications for
each agent to be evaluated increased, the size
of Working Groups has increased. Early in the
process they were sometimes as small as 10,
but now they sometimes include as many as
30 scientists. We estimate that over the entire
Monograph series, approximately 1,500 scientists have served as Working Group members,
and of course many scientists have also served
on the Advisory Groups, Scientific Council,
and Governing Council. Thus, if even a small
percentage of these scientists were disenchanted with the IARC process, it would result
in a considerable number of such individuals
and should be easy to document. To be taken
seriously, the “dissociation” criticism needs
to be supported by documented information
describing the number of scientists who have
taken this action.
Criticisms of specific evaluations. Some
criticisms of the IARC process relate to
specific agents, where it is asserted that the
hazard evaluations of category 2B, 2A, or 1
are not supported by the scientific literature.
In the 111 volumes of the Monographs
produced over the four decades since 1971,
970 agents have been considered, 114
(12%) have been classified as carcinogenic
to humans (Group 1), 69 (7%) as probably
carcinogenic (Group 2A), 283 (29%) as
possibly carcinogenic (Group 2B), 504 (52%)
as not classifiable regarding their carcinogenicity (Group 3), and 1 (< 1%) as probably
not carcinogenic to humans (Group 4). Thus,
even for this highly select group of agents
(i.e., those selected for evaluation because
there was some concern that they might be
carcinogenic), more than one-half were “not
classifiable” or “probably not carcinogenic,”
and a further 29% were placed into the
category of possibly carcinogenic to humans.
This distribution, based on nearly 1,000 evaluations in which fewer than one in five agents
were classified as carcinogenic or probably
carcinogenic to humans, does not support a
conclusion that the process is heavily biased
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toward classifying agents as carcinogenic
(Boffetta et al. 2009; Kabat 2012).
The monographs for formaldehyde, coffee,
DDT, and radiofrequency electromagnetic
radiation have been cited as examples of problematic evaluations by some (Kabat 2012)
[among these, only formaldehyde was classified as known to be carcinogenic to humans
(Group 1) by an IARC Working Group].
These are important agents. However, to
accept the charge that IARC evaluations are
fundamentally biased, one has to assume
that the scientists who were members of the
Working Groups were incapable of appropriately evaluating weaknesses in the data,
or that they distorted the evaluative process
because of personal biases. In our experience,
neither of these assertions is correct. Dissent
among scientists is not unusual in any area
of science. It is a strength of the scientific
process. The IARC process capitalizes on this
by bringing scientists from different disciplines together in one room to evaluate the
literature and to reach a reasoned conclusion.
Differences of opinion occur among Working
Group members. These differences, however,
typically involve disputes related to assignment to adjacent classification categories. It is
instructive that there are no instances in which
a carcinogen classified at the Group 1 level
by one Working Group has been reversed
by another. The recent review of all Group 1
agents for Volume 100 provided ample opportunity to reverse such previous classifications,
but none occurred. Every scientist could
probably name a substance that has been
reviewed by IARC that they might personally place in a different category from that
assigned by the Working Group, but this is
one opinion against the collective wisdom and
process of the Working Group.
Criticisms of the composition of the
working groups. The composition of the
Working Groups has also been criticized
(Erren 2011; McLaughlin et al. 2010,
2011); it has been argued that members of
the Working Groups who have conducted
research on the agents under evaluation have
a vested interest in advancing their own
research results in the deliberations. This criticism has been addressed directly by Wild and
colleagues (Wild and Cogliano 2011; Wild
and Straif 2011) from IARC, and we know
of no evidence to support this contention.
Even if some scientists on the Working Group
have performed research on some of the agents
being considered, they make up a minority of
the Working Group because several agents are
usually evaluated in a single meeting, so the
number of Working Group members who
have conducted research on any one agent
is typically small. Our experience has been
that having some scientists who are knowledgeable about the studies of the agent under
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evaluation (and can therefore answer technical
queries) and others from different, but related,
fields provides a knowledgeable and balanced
mix of scientific backgrounds for a thoughtful
evaluation of the literature.
Working Group members do not receive
any fee for their work, but they are paid travel

expenses, and there is some prestige associated with service on an IARC Monograph.
However, most scientists asked to serve on
IARC Working Groups have already achieved
some measure of scientific stature, and there
is no reason why this should bias their evaluation in one direction or the other. In addition,

Appendix 1: Classification Categories for the Overall Evaluation
for the IARC Monographs (IARC 2006)
Group 1: The agent is carcinogenic to humans.
This category is used when there is sufficient evidence of carcinogenicity in humans.
Exceptionally, an agent may be placed in this category when evidence of carcinogenicity in
humans is less than sufficient but there is sufficient evidence of carcinogenicity in experimental animals and strong evidence in exposed humans that the agent acts through a relevant
mechanism of carcinogenicity.
Group 2.
This category includes agents for which, at one extreme, the degree of evidence of carcino
genicity in humans is almost sufficient, as well as those for which, at the other extreme, there
are no human data but for which there is evidence of carcinogenicity in experimental animals.
Agents are assigned to either Group 2A (probably carcinogenic to humans) or Group 2B
(possibly carcinogenic to humans) on the basis of epidemiological and experimental evidence
of carcinogenicity and mechanistic and other relevant data. The terms probably carcinogenic
and possibly carcinogenic have no quantitative significance and are used simply as descriptors
of different levels of evidence of human carcinogenicity, with probably carcinogenic signifying a
higher level of evidence than possibly carcinogenic.
Group 2A: The agent is probably carcinogenic to humans.
This category is used when there is limited evidence of carcinogenicity in humans and sufficient
evidence of carcinogenicity in experimental animals. In some cases, an agent may be classified
in this category when there is inadequate evidence of carcinogenicity in humans and sufficient
evidence of carcinogenicity in experimental animals and strong evidence that the carcinogenesis is mediated by a mechanism that also operates in humans. Exceptionally, an agent
may be classified in this category solely on the basis of limited evidence of carcinogenicity in
humans. An agent may be assigned to this category if it clearly belongs, based on mechanistic
considerations, to a class of agents for which one or more members have been classified in
Group 1 or Group 2A.
Group 2B: The agent is possibly carcinogenic to humans.
This category is used for agents for which there is limited evidence of carcinogenicity in humans
and less than sufficient evidence of carcinogenicity in experimental animals. It may also be used
when there is inadequate evidence of carcinogenicity in humans but there is sufficient evidence
of carcinogenicity in experimental animals. In some instances, an agent for which there is
inadequate evidence of carcinogenicity in humans and less than sufficient evidence of carcino
genicity in experimental animals together with supporting evidence from mechanistic and
other relevant data may be placed in this group. An agent may be classified in this category
solely on the basis of strong evidence from mechanistic and other relevant data.
Group 3: The agent is not classifiable as to its carcinogenicity to humans.
This category is used most commonly for agents for which the evidence of carcinogenicity is
inadequate in humans and inadequate or limited in experimental animals.
Exceptionally, agents for which the evidence of carcinogenicity is inadequate in humans
but sufficient in experimental animals may be placed in this category when there is
strong evidence that the mechanism of carcinogenicity in experimental animals does not
operate in humans.
Agents that do not fall into any other group are also placed in this category.
An evaluation in Group 3 is not a determination of noncarcinogenicity or overall safety.
It often means that further research is needed, especially when exposures are widespread or
the cancer data are consistent with differing interpretations.
Group 4: The agent is probably not carcinogenic to humans.
This category is used for agents for which there is evidence suggesting lack of carcinogenicity in
humans and in experimental animals. In some instances, agents for which there is inadequate
evidence of carcinogenicity in humans but evidence suggesting lack of carcinogenicity in experimental animals, consistently and strongly supported by a broad range of mechanistic and
other relevant data, may be classified in this group.

volume

123 | number 6 | June 2015 • Environmental Health Perspectives

IARC Monographs

IARC strictly requires that any conflict of
interests be divulged, and does not allow those
with conflicts of interest to serve on Working
Groups, although nonvoting observers who
may have conflicts of interest are able to attend
the Working Group meetings.

Conclusions
For more than four decades the IARC
Monograph Programme has provided evaluations of cancer hazards to humans from many
different exposures and agents. These are often
the first evaluations of new and emerging
threats to public health and, consequently,
are subject to intense scrutiny. Although these
evaluations are widely respected and used by
many organizations, institutions, companies,
and government agencies to improve the
public’s health, IARC has recently been subject
to criticism over conclusions on specific agents,
the process that leads to such conclusions,
and membership of the Working Groups.
Debate and criticism facilitate self-correction
and a check on the validity in science. We
are concerned, however, that the criticisms
expressed by a vocal minority regarding the
evaluations of a few agents may promote the
denigration of a process that has served the
public and public health well for many decades
for reasons that are not supported by data.
There has been very broad involvement
of the scientific community in the IARC
Monograph Programme through participation in the Working Groups and service
on the IARC Governing and Scientific
Councils and ad hoc Advisory Board for
the Monograph Programme. The long list
of scientists who are coauthors of this paper
attests to the strong support that IARC has
in the scientific community. Many exposures
that IARC has evaluated have also been
independently evaluated by other institutions, such as the U.S. National Toxicology
Program (https://ntp.niehs.nih.gov/); U.S.
Environmental Protection Agency (http://
www.epa.gov/); National Academy of
Sciences (http://www.nasonline.org/); the
American Conference of Governmental
Industrial Hygienists (ACGIH) Threshold
Limit Values and Biological Exposure Indices
(http://www.acgih.org/); the Nordic Expert
Group for Criteria Documentation of
Health Risks from Chemicals (http://www.
av.se/arkiv/neg/); Institute of Occupational
Medicine (http://www.iom-world.org/);
World Cancer Research Fund/American
Institute for Cancer Research (WCRF/
AICR) Expert Reports; European Chemicals
Agency (https://echa.europa.eu); Swedish
Criteria Group for Occupational Standards
(2013); California Office of Environmental
Hazard Assessment (Proposition 65; http://
oehha.ca.gov/prop65/background/p65plain.
html); Health Canada Bureau of Chemical
Environmental Health Perspectives •
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Safety (http://www.hc-sc.gc.ca/ahc-asc/
branch-dirgen/hpfb-dgpsa/fd-da/bcs-bsc/
index-eng.php); Scientific Committee on
Occupational Exposure Limits (SCOEL),
European Commission, Employment, Social
Affairs and Inclusion (http://ec.europa.eu/
social/main.jsp?catId=148&langId=en&intPa
geId=684); European Food Safety Authority
(EFSA 2013); and European Chemicals
Agency (ECHA; http://echa.europa.eu/).
Assessments from these groups typically come
to conclusions similar to those from IARC.
This further indicates broad agreement within
the scientific community regarding evidence
on carcinogenicity in the scientific literature
and expands the number of scientists who
do not have a “vested interest” but who have
generally agreed with those conclusions.
Disagreement with the conclusions in an
IARC Monograph for an individual agent is
not evidence for a failed or biased approach.
Some disagreement about the carcinogenic
hazard of important agents seems inherent to
the scientific enterprise and is unavoidable at
early stages of the hazard evaluation, where
IARC usually operates. Because the evaluations are not—and should not be—static, it
is difficult to see how such assessments could
be addressed any differently. Substances now
universally recognized as human carcinogens
(e.g., tobacco, asbestos) at one time went
through a quite lengthy period of contentious
debate (Michaels 2006, 2008). Any process
can in theory be improved with fair and
constructive criticism; appropriate reviews may
take place from time to time, and we would
support continued review and improvement
of the IARC processes. However, as a group of
international scientists, we have looked carefully at the recent charges of flaws and bias
in the hazard evaluations by IARC Working
Groups, and we have concluded that the recent
criticisms are unfair and unconstructive.
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